Attorney Docket No.: ASTXNA00101

I hereby certify that this correspondence is being electropically transmitted to the USPTO on the date shown below.

(VAIAA) N

Date: July 26, 2007

Signature:

(Quyen Nguyen)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/810,276

Confirmation No.:

8525

Filing Date:

March 26, 2004

Inventor(s):

Michael D. LAUFER

Title:

METHODS OF TREATING AIRWAYS IN THE LUNG

Examiner:

D. Shay

Group Art Unit:

3735

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patent P.O. Box 1450 Alexandria, VA 22313-1450

Sir

Pursuant to 37 C.F.R. §1.97 and §1.98, Applicants submit for consideration in the above-captioned application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. §1.97(e)(I) has been provided.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. §1.97 and §1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this

Attorney Docket No.: ASTXNA00101 Application No.: 10/810,276

application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the event the appropriate fee and/or petition is not filed herewith and the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with this filing to Deposit Account No. 50-3973 referencing Attorney Docket No.

ASTXNA00101. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Laura L. Shires

Registration No. 52,222

Customer No. 40518

Levine Bagade Han LLP

2483 East Bayshore Road, Suite 100

Palo Alto, CA 94303

Direct: (650) 242-4211

Fax: (650) 284-2180

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/810,276	
INFORMATION DISCLOSURE				Filing Date	3/26/2004	
STAT	STATEMENT BY APPLICANT			First Named Inventor	LAUFER, Michael D.	
(Use as many sheets as necessary)				Art Unit	3735	
				Examiner Name	Shay, David M.	
Sheet	1 4	of	7 7	Attorney Docket No: AST	Y-N-A001 01-119	·i

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), vo issue number(s), publisher, city and/or country where published.					
		AN, S.S et al., Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma, European Respiratory Journal, 2007, Volume 29, Number 5, pp. 834-860.				
***************************************		BEL, E. H., Hot Stuff: Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, Volume 173, pp. 941-942.				
		BROWN, R. H. et al., In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography, Journal of Applied Physiology, 2005, Volume 98, pp. 1603-1606.				
		BROWN, R. H. et al., Effect of bronchial thermoplasty on airway distensibility, European Respiratory Journal, Volume 26, NUMBER 2, pp. 277-282.				
		CHHAJED, P., Will There be a Role for Bronchoscopic Radiofrequency Ablation?, 2005. J Bronchol, Volume 12, Number 3, p. 184.				
		COX, G., et al., Early Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma, 2002, p. 1068.				
		COX, G. et al., Asthma Control During the Year After Bronchial Thermoplasty, The New England Journal of Medicine, March 29, 2007, Volume 356, Number 13, pp. 1327-1337.				
		COX, G. et al., Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting, 2004, p. 1.				
		COX, G., et al., Development of a Novel Bronchoscopic Therapy for Asthma, Journal of Allergy and Clinical				
		COX, G., et al., Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, Volume 173, pp. 965-969.	<u> </u>			
		COX, G., et al., Bronchial Thermoplasty: Long-Term Follow-up and Patient Satisfaction, 2004, p. 1.				
		COX, G., et al., Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations, European Respiratory Journal, 2004, 24, pp. 659–663.	<u> </u>			
		COX, G., et al., Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, 2003, Chest 124, p. 106S.				
		COX, G., et al., Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial, 2006, European Respiratory Society Annual Meeting, Munich, Germany, p. 1.	<u> </u>			
	••••	DANEK, C. J., et al., Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, 2002, American Thoracic Society Annual Meeting, p. 1.	<u> </u>			
		DANEK, C. J., et al., Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty TM : Early Results, 2002, American Thoracic Society Annual Meeting, p. 1.	<u> </u>			
	•••••	DANEK, C. J., et al., Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs, J Appl Physiol, 2004, Volume 97, pp. 1946-1953.	<u> </u>			
		SOLWAY, J. at al., Airway Smooth Muscle as a Target for Asthma Therapy, The New England Journal of Medicine, March 29, 2007, 356(13), pp. 1367-1369.				

EXAMINER SIGNATURE DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant: Applicant's unique citation designation number (optional), z. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), a For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. sApplicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/810,276	
INFORMATION DISCLOSURE				Filing Date	3/26/2004	
STAT	STATEMENT BY APPLICANT			First Named Inventor	LAUFER, Michael D.	
(Use as many cheets as necessary)				Art Unit	3735	
				Examiner Name	Shay, David M.	
Sheet	2	of	2	Attorney Docket No: AST	X-N-A001.01-US	

444444444		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lssue number(s), publisher, city and/or country where published.			
		LAVIOLETTE, et al., Asthma Intervention Research (AIR) Trial: Early Safety Assessment of Bronchial Thermoplasty, 2004, p. 1.			
		LEFF, et al., Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Responsiveness in Dogs: A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting, 2002, p. 1.	†		
		LIM, E. C. et al., Botulinum Toxin: A Novel Therapeutic Option for Bronchial Asthma?, Medical Hypotheses, 2006, Volume 66, pp. 915-919.			
		LOMBARD, et al., Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting, 2002, p. 1.			
		MAYSE, M. et al., Clinical Pearls for Bronchial Thermoplasty, J Bronchol, Apr-2007, Volume 14, Number 2, pp. 115-123.			
		MILLER, J. D. et al., A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway, 2005, Volume 127, Number 6, pp. 1999-2006.			
		MILLER, J. D. et al., Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, 2002, American Thoracic Society Annual Meeting, p. 1.			
		RUBIN, et al. Bronchial Thermoplasty Improves Asthma Status of Moderate to Severe Peristent Asthmatics Over and Above Current Standard-of-Care, 2006, American College of Chest Physicians, 2 pages.			
		WILSON, S. R. et al., Global assessment after bronchial thermoplasty: the patient's perspective, Journal of Outcomes Research, 2006, Volume 10, pp. 37-46.			
		STERK, P. J., Heterogeneity of Airway Hyperresponsiveness: Time for Unconventional, but Traditional Studies, 2004, The American Pshychological Society, pp. 2017-18.			
		TOMA, T. P., Brave New World for Interventional Bronchoscopy, 2005, Thorax, Volume 60, pp. 180-181.			
		TROW, T., Clinical Year in Review 1, proceedings of the American Thoracic Society, 2006, Volume 3, pp. 553-556.			
		WIZEMAN, et al., A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, 2007, American Thoracic Society Annual Meeting, p. 1.			
		VASILOTTA, P. L. et al., "I-R Laser: A New Therapy in Rhino-Sino-Nasal Bronchial Syndrome with Asthmatic Component," American Society for Laser medicine and Surgery abstracts, date unknown, p. 74.			
		SHESTERINA, M. V. et al., Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis, 1993, pp. 23–26.			

EXAMINER SIGNATURE	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible, a Applicant is to place a check mark here if English language

Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.